A summary of the effects of the restatement on the applicable line items within the Company’s consolidated balance sheet as of December 31, 2015 is as follows:

	Consolidated Balance Sheet as of December 31, 2015
	As Reported		Adjustments		Restated
Inventories	$	18,685	$	(30)	$	18,655
Total current assets		128,524		(30)		128,494
Property, plant and equipment		63,940		(27)		63,913
Total assets		202,984		(57)		202,927
Accounts payable and accrued liabilities		22,524		137		22,661
Total current liabilities		58,001		137		58,138
Other non-current liabilities		756		2,042		2,798
Total long-term liabilities		6,242		2,042		8,284
Total liabilities		64,243		2,179		66,422
Accumulated other comprehensive income		8,110		72		8,182
Accumulated deficit		(8,281)		(1,699)		(9,980)
Total shareholders’ equity		123,280		(1,627)		121,653
Non-controlling interest		15,461		(609)		14,852
Total equity		138,741		(2,236)		136,505
Total liabilities and equity		202,984		(57)		202,927

A summary of the effects of the restatement on the applicable line items within the Company’s consolidated statements of comprehensive loss for the years ended December 31, 2015 and 2014 is as follows:

	Consolidated Statement of Comprehensive Loss For the year ended December 31, 2015
	As Reported		Adjustments		Restated
Cost of sales	$	18,425	$	(17)	$	18,408
Gross profit		48,989		17		49,006
Selling, general and administrative expenses		37,436		45		37,481
Total operating expenses		45,266		45		45,311
Operating income		3,723		(28)		3,695
Other income (expenses)		73		(247)		(174)
Income from continuing operations before income taxes		3,031		(275)		2,756
Income tax expense		(2,516)		(469)		(2,985)
Income (loss) from continuing operations		515		(744)		(229)
Net loss		(213)		(744)		(957)
Income attributable to non-controlling interest		(861)		402		(459)
Net loss attributable to shareholders of Sinovac		(1,074)		(342)		(1,416)
Income (loss) from continuing operations		515		(744)		(229)
Foreign currency translation adjustments		(4,137)		90		(4,047)
Comprehensive loss from continuing operations		(3,622)		(654)		(4,276)
Comprehensive loss		(4,688)		(654)		(5,342)
Comprehensive (income) loss attributable to non-controlling interest		(298)		380		82
Comprehensive loss attributable to shareholders of Sinovac		(4,986)		(274)		(5,260)
Basic net loss per share - continuing operations		(0.01)		(0.01)		(0.02)
Basic net loss per share attributable to shareholders of Sinovac		(0.02)		(0.01)		(0.03)
Diluted net loss per share - continuing operations		(0.01)		(0.01)		(0.02)
Diluted net loss per share attributable to shareholders of Sinovac		(0.02)		(0.01)		(0.03)

	Consolidated Statement of Comprehensive Loss For the year ended December 31, 2014
	As Reported		Adjustments		Restated
Selling, general and administrative expenses	$	34,166	$	172	$	34,338
Total operating expenses		45,399		172		45,571
Operating income		2,057		(172)		1,885
Other income		1,312		(126)		1,186
Income from continuing operations before income taxes		2,646		(298)		2,348
Income tax expense		(1,458)		(611)		(2,069)
Income from continuing operations		1,188		(909)		279
Net loss		(336)		(909)		(1,245)
Income attributable to non-controlling interest		(515)		245		(270)
Net loss attributable to shareholders of Sinovac		(851)		(664)		(1,515)
Income from continuing operations		1,188		(909)		279
Foreign currency translation adjustments		(2,344)		24		(2,320)
Comprehensive loss from continuing operations		(1,156)		(885)		(2,041)
Comprehensive loss		(2,763)		(885)		(3,648)
Comprehensive income attributable to non-controlling interest		(207)		242		35
Comprehensive loss attributable to shareholders of Sinovac		(2,970)		(643)		(3,613)
Basic net income per share - continuing operations		0.01		(0.01)		0.00
Basic net loss per share attributable to shareholders of Sinovac		(0.02)		(0.01)		(0.03)
Diluted net income per share - continuing operations		0.01		(0.01)		0.00
Diluted net loss per share attributable to shareholders of Sinovac		(0.02)		(0.01)		(0.03)

A summary of the effects of the restatement on the applicable line items within the Company’s consolidated statement of cash flows for the years ended December 31, 2015 and 2014 is as follows

	Consolidated Statement of Cash Flows for the year ended December 31, 2015
	As Reported		Adjustments		Restated
Income (loss) from continuing operations	$	515	$	(744)	$	(229)
Deferred income taxes		(518)		185		(333)
Depreciation of property, plant and equipment and amortization of licenses		6,249		9		6,258
Inventories		10		18		28
Accounts payable and accrued liabilities		(434)		136		(298)
Other non-current liabilities		333		446		779
Time deposits		-		1,500		1,500
Net cash provided by operating activities from continuing operations		3,383		1,550		4,933
Net cash provided by operating activities		2,661		1,550		4,211
Effect of exchange rate changes on cash and cash equivalents, including cash classified within current assets held for sale		(1,491)		(50)		(1,541)
Decrease in cash and cash equivalents, including cash classified within current assets held for sale		(27,541)		1,500		(26,041)
Decrease in cash and cash equivalents, including cash from discontinued operation		(27,459)		1,500		(25,959)
Cash and cash equivalents, beginning of year		91,293		(1,500)		89,793

	Consolidated Statement of Cash Flows for the year ended December 31, 2014
	As Reported		Adjustments		Restated
Income from continuing operations	$	1,188	$	(909)	$	279
Deferred income taxes		(162)		(63)		(225)
Depreciation of property, plant and equipment and amortization of licenses		7,829		8		7,837
Accounts payable and accrued liabilities		(3,999)		506		(3,493)
Other non-current liabilities		454		478		932
Time deposits		-		(1,500)		(1,500)
Net cash provided by operating activities from continuing operations		(7,524)		(1,480)		(9,004)
Net cash provided by operating activities		(8,647)		(1,480)		(10,127)
Effect of exchange rate changes on cash and cash equivalents, including cash classified within current assets held for sale		(1,383)		(20)		(1,403)
Increase (decrease) in cash and cash equivalents, including cash classified within current assets held for sale		(15,724)		(1,500)		(17,224)
Decrease in cash and cash equivalents, including cash from discontinued operation		(15,224)		(1,500)		(16,724)
Cash and cash equivalents, end of year		91,293		(1,500)		89,793